Company Description

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.

It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

The company was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

Country	Switzerland
Founded	2021
Industry	Biotechnology
Sector	Healthcare
Employees	130
CEO	Jorge da Silva

Contact Details

Address: Dorfstrasse 29 Zug, 6300 Switzerland
Phone	41 415108022
Website	moonlaketx.com

Stock Details

Ticker Symbol	MLTX
Exchange	NASDAQ
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1821586
CUSIP Number	61559X104
ISIN Number	KY61559X1045
SIC Code	2834

Key Executives

Name	Position
Dr. Kristian Reich M.D., Ph.D.	Co-Founder and Chief Scientific Officer
Matthias Bodenstedt	Chief Financial Officer
Oliver Daltrop Ph.D.	Chief Operations Officer
Carla Bretes	Director of Investor Relations and External Communications
Nicolas Mosimann Ph.D.	General Counsel
Joana Cortez	Associate Vice-President of Legal and Compliance
Tino Anthamatten	Vice President of Marketing, Market Access and Pricing
Luciana Marques	Associate Vice-President of Human Resources, People and Culture
Nuala Brennan	Chief Clinical Development Officer
Roman Akbar-Haase	Chief of Staff to the Executive Board

Latest SEC Filings

Date	Type	Title
Feb 25, 2026	10-K	Annual Report
Feb 23, 2026	8-K	Current Report
Feb 17, 2026	SCHEDULE 13G	Filing
Jan 8, 2026	8-K	Current Report
Dec 8, 2025	144	Filing
Dec 8, 2025	144	Filing
Nov 14, 2025	SCHEDULE 13G/A	Filing
Nov 12, 2025	SCHEDULE 13G	Filing
Nov 10, 2025	SCHEDULE 13D/A	Filing
Nov 5, 2025	8-K	Current Report

View All SEC Filings